Dubai releases Belgian drug lord facing 51-year sentence, raising pharmacy control questions

Dubai authorities have released Omar Govers, a Belgian drug trafficker facing 51 years and nine months of prison sentences in Belgium, after he was detained in Dubai for just under one year, according to The Brussels Times on 13 October 2026.

The healthcare readers with most at stake are pharmacy COOs, medical directors and insurers. The case is a criminal justice story. For Dubai clinics and pharmacies, it is also a reminder that narcotic, psychotropic and semi-controlled medicines sit inside a tightly regulated chain that links prescribers, dispensers, importers, insurers and patients.

What happened in Dubai

The Brussels Times reported that Govers was arrested at the request of Belgian judicial authorities and has now been released by Dubai authorities. It said Belgian courts have confiscated more than €411 million of assets tied to him, and that a pending case could add 12 years to his sentence if he is convicted.

His record includes a 2019 conviction by the Antwerp Court of Appeal for leading a gang that sold cocaine under the alias Patje Haemers. His lawyer declined to comment to Gazet van Antwerpen, according to the Brussels report. The open question is whether he will be extradited to Belgium.

For UAE healthcare operators, the relevant point is narrower. Dubai's private clinics and pharmacies are regulated by the Dubai Health Authority (DHA). Abu Dhabi and Al Ain providers are regulated by the Department of Health Abu Dhabi (DOH). Northern emirates providers sit under the Ministry of Health and Prevention (MOHAP), with federal drug classifications now tied to the Emirates Drug Establishment.

Why clinics and pharmacies should care

DHA says its Drug Control section oversees medication governance in Dubai, including approvals linked to controlled, semi-controlled, narcotic, prescription-only and general medicines. The UAE government portal states that narcotic and psychotropic medicines are controlled drugs and must be prescribed through official channels.

That matters because high-profile drug trafficking cases can raise the scrutiny applied to legal controlled-medicine flows. The operational exposure is routine: incomplete prescriptions, weak identity checks, stock discrepancies, poor destruction records and insurance claims that fail audit review.

• Dubai providers: confirm controlled-medicine prescribing and dispensing workflows against DHA circulars and Sheryan licence conditions.
• Abu Dhabi and Al Ain providers: DOH activated the inventory management module of the national platform for narcotic and controlled medicines from 15 July 2024.
• Northern emirates providers: check MOHAP requirements for import, storage, dispensing and transfer of narcotic, psychotropic and semi-controlled medicines.
• Insurers: Daman, Thiqa and Sukoon claims teams should ensure pharmacy claims for controlled medicines have valid prescriber, patient and dispensed-quantity data.

The cost signal is also specific. MOHAP's services guide lists an AED 100 application fee for importing controlled medicines and a fee of 1% of invoice value, with a minimum of AED 200 for each narcotic-drug import permit. That figure applies to the permit route described by MOHAP, not to a retail patient's copay.

For patients, the actionable number is the UAE personal-use limit. MOHAP guidance for travellers allows narcotic and psychotropic medicines for the period of stay, capped at a maximum of three months, with medical justification and supporting documents. Residents should ask the treating UAE physician and pharmacist whether a medicine is listed as controlled before travel or refill.

What operators should check next

Clinic and pharmacy leaders should treat the Govers case as a compliance prompt, especially in Dubai where international patient flows are high. A practical review can be completed in 30 days if the facility already has a named pharmacist-in-charge, current licences and electronic prescribing access.

The review should cover four items: prescriber eligibility, Emirates ID or passport verification, physical and electronic stock reconciliation, and insurer documentation for reimbursed prescriptions. Medical directors should add a second check for specialties that commonly prescribe controlled medicines, including psychiatry, pain medicine, oncology, neurology and anaesthesia.

Patients should avoid price-shopping for controlled medicines across multiple pharmacies without a valid UAE prescription pathway. Retail prices and copays vary by molecule, dose, pack size and insurance policy. The reliable route is to ask the insurer for formulary status and the licensed pharmacy for the dispensed brand, pack and DHA, DOH or MOHAP classification before payment.

The UAE enforcement issue will remain separate from Belgian extradition politics. For healthcare operators, the next measurable task is internal: prove that every controlled medicine has a licensed prescriber, a verified patient, a compliant stock trail and a defensible claim record. To find licensed providers, patients and operators can use the UAE Open Healthcare Directory, which lists licensed pharmacy providers across Dubai, Abu Dhabi, Al Ain and the northern emirates.